

Jianlin Gong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7617058/publications.pdf>

Version: 2024-02-01

91
papers

4,844
citations

76326

40
h-index

95266

68
g-index

92
all docs

92
docs citations

92
times ranked

5039
citing authors

#	ARTICLE	IF	CITATIONS
1	Heat Shock Proteins Promote Cancer: It's a Protection Racket. <i>Trends in Biochemical Sciences</i> , 2016, 41, 311-323.	7.5	316
2	Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses. <i>Clinical Cancer Research</i> , 2004, 10, 4699-4708.	7.0	227
3	Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity. <i>Journal of Immunology</i> , 2000, 165, 1705-1711.	0.8	211
4	mTOR Is Essential for the Proteotoxic Stress Response, HSF1 Activation and Heat Shock Protein Synthesis. <i>PLoS ONE</i> , 2012, 7, e39679.	2.5	187
5	Induction of Antitumor Immunity by Vaccination of Dendritic Cells Transfected with MUC1 RNA. <i>Journal of Immunology</i> , 2000, 165, 5713-5719.	0.8	164
6	Extracellular HSPs: The Complicated Roles of Extracellular HSPs in Immunity. <i>Frontiers in Immunology</i> , 2016, 7, 159.	4.8	155
7	Hsp70- β 3 Interactions Regulate Cancer-Related Signaling Networks. <i>Cancer Research</i> , 2014, 74, 4731-4740.	0.9	141
8	The Role of Heat Shock Proteins in Antigen Cross Presentation. <i>Frontiers in Immunology</i> , 2012, 3, 63.	4.8	137
9	Message in a bottle: Role of the 70-kDa heat shock protein family in anti-tumor immunity. <i>European Journal of Immunology</i> , 2005, 35, 2518-2527.	2.9	130
10	Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. <i>Blood</i> , 2002, 99, 2512-2517.	1.4	120
11	Induction of heat shock proteins by heregulin β 1 leads to protection from apoptosis and anchorage-independent growth. <i>Oncogene</i> , 2005, 24, 6564-6573.	5.9	107
12	Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)-Specific MHC Class I/II-Restricted Epitopes for Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4228-4239.	7.0	105
13	Heat Shock Protein 90 Mediates Efficient Antigen Cross Presentation through the Scavenger Receptor Expressed by Endothelial Cells-I. <i>Journal of Immunology</i> , 2010, 185, 2903-2917.	0.8	95
14	Elevated Expression of Heat Shock Factor (HSF) 2A Stimulates HSF1-induced Transcription during Stress. <i>Journal of Biological Chemistry</i> , 2003, 278, 35465-35475.	3.4	91
15	Enhanced Immunogenicity of Heat Shock Protein 70 Peptide Complexes from Dendritic Cell-Tumor Fusion Cells. <i>Journal of Immunology</i> , 2006, 177, 5946-5955.	0.8	89
16	Dendritic Cells Fused with Allogeneic Colorectal Cancer Cell Line Present Multiple Colorectal Cancer-Specific Antigens and Induce Antitumor Immunity against Autologous Tumor Cells. <i>Clinical Cancer Research</i> , 2005, 11, 7891-7900.	7.0	84
17	Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come. <i>Expert Review of Vaccines</i> , 2011, 10, 1553-1568.	4.4	83
18	HSF1 regulation of β -catenin in mammary cancer cells through control of HuR/elavL1 expression. <i>Oncogene</i> , 2015, 34, 2178-2188.	5.9	83

#	ARTICLE	IF	CITATIONS
19	A Heat Shock Protein 70-Based Vaccine with Enhanced Immunogenicity for Clinical Use. <i>Journal of Immunology</i> , 2010, 184, 488-496.	0.8	80
20	Prevention of Spontaneous Breast Carcinoma by Prophylactic Vaccination with Dendritic/Tumor Fusion Cells. <i>Journal of Immunology</i> , 2003, 170, 1980-1986.	0.8	78
21	How is the immune response affected by hyperthermia and heat shock proteins?. <i>International Journal of Hyperthermia</i> , 2005, 21, 713-716.	2.5	77
22	Immunotherapy for colorectal cancer. <i>World Journal of Gastroenterology</i> , 2013, 19, 8531.	3.3	76
23	T Cell Activation by Heat Shock Protein 70 Vaccine Requires TLR Signaling and Scavenger Receptor Expressed by Endothelial Cells-1. <i>Journal of Immunology</i> , 2009, 183, 3092-3098.	0.8	75
24	Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. <i>British Journal of Haematology</i> , 2004, 125, 343-352.	2.5	74
25	Cell surface receptors for molecular chaperones. <i>Methods</i> , 2007, 43, 199-206.	3.8	74
26	Heat-shock proteins in cancer vaccines: agents of antigen cross-presentation. <i>Expert Review of Vaccines</i> , 2008, 7, 1019-1030.	4.4	70
27	Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. <i>Journal of Gastroenterology</i> , 2001, 36, 764-771.	5.1	68
28	Vaccination with Allogeneic Dendritic Cells Fused to Carcinoma Cells Induces Antitumor Immunity in MUC1 Transgenic Mice. <i>Clinical Immunology</i> , 2001, 101, 192-200.	3.2	67
29	Bone Marrow and Peripheral Blood Dendritic Cells From Patients With Multiple Myeloma Are Phenotypically and Functionally Normal Despite the Detection of Kaposi's Sarcoma Herpesvirus Gene Sequences. <i>Blood</i> , 1999, 93, 1487-1495.	1.4	66
30	The Kinetics of In Vivo Priming of CD4 and CD8 T Cells by Dendritic/Tumor Fusion Cells in MUC1-Transgenic Mice. <i>Journal of Immunology</i> , 2002, 168, 2111-2117.	0.8	66
31	Current Immunotherapeutic Approaches in Pancreatic Cancer. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-15.	3.3	66
32	Expression of a Dominant Negative Heat Shock Factor-1 Construct Inhibits Aneuploidy in Prostate Carcinoma Cells*. <i>Journal of Biological Chemistry</i> , 2004, 279, 32651-32659.	3.4	64
33	Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. <i>Immunology</i> , 2003, 109, 300-307.	4.4	63
34	Dendritic cells fused with human cancer cells: morphology, antigen expression, and T cell stimulation. <i>Clinical Immunology</i> , 2004, 113, 261-269.	3.2	59
35	Metastasis is an early event in mouse mammary carcinomas and is associated with cells bearing stem cell markers. <i>Breast Cancer Research</i> , 2012, 14, R18.	5.0	56
36	Molecular chaperones in mammary cancer growth and breast tumor therapy. <i>Journal of Cellular Biochemistry</i> , 2012, 113, 1096-1103.	2.6	52

#	ARTICLE	IF	CITATIONS
37	Cell fusion: from hybridoma to dendritic cell-based vaccine. <i>Expert Review of Vaccines</i> , 2008, 7, 1055-1068.	4.4	49
38	Investigating Receptors for Extracellular Heat Shock Proteins. <i>Methods in Molecular Biology</i> , 2011, 787, 289-302.	0.9	48
39	Immunotherapy of Radioresistant Mammary Tumors with Early Metastasis Using Molecular Chaperone Vaccines Combined with Ionizing Radiation. <i>Journal of Immunology</i> , 2013, 191, 755-763.	0.8	46
40	Scavenger Receptor SREC-I Mediated Entry of TLR4 into Lipid Microdomains and Triggered Inflammatory Cytokine Release in RAW 264.7 Cells upon LPS Activation. <i>PLoS ONE</i> , 2015, 10, e0122529.	2.5	43
41	Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells. <i>International Journal of Cancer</i> , 2011, 129, 1990-2001.	5.1	41
42	Heat Shock Proteins: Conditional Mediators of Inflammation in Tumor Immunity. <i>Frontiers in Immunology</i> , 2012, 3, 75.	4.8	40
43	Hsp90-peptide complexes stimulate antigen presentation through the class II pathway after binding scavenger receptor SREC-I. <i>Immunobiology</i> , 2014, 219, 924-931.	1.9	39
44	Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. <i>Leukemia Research</i> , 2004, 28, 1303-1312.	0.8	38
45	Fusions between dendritic cells and whole tumor cells as anticancer vaccines. <i>Oncolmmunology</i> , 2013, 2, e24437.	4.6	38
46	Induction of antigen-specific CD4- and CD8-mediated T-cell responses by fusions of autologous dendritic cells and metastatic colorectal cancer cells. <i>International Journal of Cancer</i> , 2005, 117, 587-595.	5.1	37
47	Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. <i>Gynecologic Oncology</i> , 2005, 99, 462-471.	1.4	34
48	Synergistic Induction of Antigen-Specific CTL by Fusions of TLR-Stimulated Dendritic Cells and Heat-Stressed Tumor Cells. <i>Journal of Immunology</i> , 2007, 179, 4874-4883.	0.8	34
49	Induction of Impaired Antitumor Immunity by Fusion of MHC Class II-Deficient Dendritic Cells with Tumor Cells. <i>Journal of Immunology</i> , 2005, 174, 1274-1280.	0.8	32
50	Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-14.	3.3	31
51	Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells. <i>Vaccine</i> , 2007, 25, 2610-2619.	3.8	29
52	Cancer Vaccine by Fusions of Dendritic and Cancer Cells. <i>Clinical and Developmental Immunology</i> , 2009, 2009, 1-13.	3.3	28
53	Scavenger receptor SREC-I promotes double stranded RNA-mediated TLR3 activation in human monocytes. <i>Immunobiology</i> , 2015, 220, 823-832.	1.9	28
54	T cell suppression as a mechanism for tolerance to MUC1 antigen in MUC1 transgenic mice. <i>Breast Cancer Research and Treatment</i> , 2000, 60, 107-115.	2.5	25

#	ARTICLE	IF	CITATIONS
55	Development of Antigen-Specific CD8+ CTL in MHC Class I-Deficient Mice through CD4 to CD8 Conversion. <i>Journal of Immunology</i> , 2004, 172, 7848-7858.	0.8	25
56	Dendritic/tumor fusion cell-based vaccination against cancer. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2007, 55, 281-287.	2.3	25
57	Combined TLR2/4-Activated Dendritic/Tumor Cell Fusions Induce Augmented Cytotoxic T Lymphocytes. <i>PLoS ONE</i> , 2013, 8, e59280.	2.5	25
58	Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy. <i>Anticancer Research</i> , 2014, 34, 6353-61.	1.1	23
59	In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells. <i>Journal of Translational Medicine</i> , 2008, 6, 51.	4.4	21
60	Cancer immunotherapy by fusions of dendritic cells and tumor cells. <i>Immunotherapy</i> , 2009, 1, 49-62.	2.0	21
61	Telomerase deficiency and telomere dysfunction inhibit mammary tumors induced by polyomavirus middle T oncogene. <i>Oncogene</i> , 2009, 28, 4225-4236.	5.9	20
62	Dendritic/pancreatic carcinoma fusions for clinical use: Comparative functional analysis of healthy-versus patient-derived fusions. <i>Clinical Immunology</i> , 2010, 135, 384-400.	3.2	19
63	Targeted imaging of breast tumor progression and therapeutic response in a human uMUC1 expressing transgenic mouse model. <i>International Journal of Cancer</i> , 2013, 132, 1860-1867.	5.1	18
64	Augmentation of Antitumor Immunity by Fusions of Ethanol-Treated Tumor Cells and Dendritic Cells Stimulated via Dual TLRs through TGF- β 1 Blockade and IL-12p70 Production. <i>PLoS ONE</i> , 2013, 8, e63498.	2.5	16
65	Characterization of structure and direct antigen presentation by dendritic/tumor-fused cells as cancer vaccines. <i>Anticancer Research</i> , 2013, 33, 347-54.	1.1	16
66	Preparation of a Heat-Shock Protein 70-Based Vaccine from DC-Tumor Fusion Cells. <i>Methods in Molecular Biology</i> , 2011, 787, 255-265.	0.9	15
67	Genotoxic stress induces Sca1-expressing metastatic mammary cancer cells. <i>Molecular Oncology</i> , 2018, 12, 1249-1263.	4.6	15
68	Tumor regression by CD4 T-cells primed with dendritic/tumor fusion cell vaccines. <i>Anticancer Research</i> , 2014, 34, 3917-24.	1.1	14
69	Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions. <i>Oncolmmunology</i> , 2013, 2, e25994.	4.6	13
70	Chemoimmunotherapy targeting Wilms' tumor 1 (WT1)-specific cytotoxic T lymphocyte and helper T cell responses for patients with pancreatic cancer. <i>Oncolmmunology</i> , 2014, 3, e958950.	4.6	13
71	Radiosensitization of mammary carcinoma cells by telomere homolog oligonucleotide pretreatment. <i>Breast Cancer Research</i> , 2010, 12, R71.	5.0	12
72	Cell Stress Proteins: Novel Immunotherapeutics. <i>Novartis Foundation Symposium</i> , 2008, 291, 115-136.	1.1	11

#	ARTICLE	IF	CITATIONS
73	Immunotherapy synergizes with chemotherapy targeting pancreatic cancer. <i>Immunotherapy</i> , 2012, 4, 5-7.	2.0	11
74	Cellular and molecular chaperone fusion vaccines: Targeting resistant cancer cell populations. <i>International Journal of Hyperthermia</i> , 2013, 29, 376-379.	2.5	10
75	Dendritic-tumor fusion cells in cancer immunotherapy. <i>Discovery Medicine</i> , 2015, 19, 169-74.	0.5	10
76	Antigen-Specific Polyclonal Cytotoxic T Lymphocytes Induced by Fusions of Dendritic Cells and Tumor Cells. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-12.	3.0	9
77	Immunologic Monitoring of Cellular Responses by Dendritic/Tumor Cell Fusion Vaccines. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-13.	3.0	9
78	Molecular Chaperone Receptors. <i>Methods in Molecular Biology</i> , 2018, 1709, 331-344.	0.9	8
79	Purification, Preparation, and Use of Chaperone-Peptide Complexes for Tumor Immunotherapy. <i>Methods in Molecular Biology</i> , 2013, 960, 209-217.	0.9	7
80	Improved immunogenicity of fusions between ethanol-treated cancer cells and dendritic cells exposed to dual TLR stimulation. <i>Oncolmmunology</i> , 2013, 2, e25375.	4.6	7
81	Induction of antigen-specific cytotoxic T lymphocytes by fusion cells generated from allogeneic plasmacytoid dendritic and tumor cells. <i>International Journal of Oncology</i> , 2014, 45, 470-478.	3.3	7
82	Cell Fusion Between Dendritic Cells and Whole Tumor Cells. <i>Methods in Molecular Biology</i> , 2015, 1313, 185-191.	0.9	6
83	A Novel Heat Shock Protein 70-based Vaccine Prepared from DC-Tumor Fusion Cells. <i>Methods in Molecular Biology</i> , 2018, 1709, 359-369.	0.9	4
84	A Workflow Guide to RNA-seq Analysis of Chaperone Function and Beyond. <i>Methods in Molecular Biology</i> , 2018, 1709, 233-252.	0.9	3
85	Molecular Chaperones and Scavenger Receptors: Binding and Trafficking of Molecular Chaperones by Class F and Class H Scavenger Receptors. <i>Heat Shock Proteins</i> , 2012, , 215-227.	0.2	3
86	Immunotherapy of Cancer Based on DC-Tumor Fusion Vaccine. <i>Current Immunology Reviews</i> , 2006, 2, 291-304.	1.2	2
87	Hsp70-Based Anticancer Vaccines: Chaperoning The Immune Response. , 2007, , 367-382.		2
88	Cancer vaccines: methods for inducing immunity. <i>Expert Review of Vaccines</i> , 2008, 7, 861-862.	4.4	1
89	The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions. <i>Oncolmmunology</i> , 2013, 2, e24660.	4.6	1
90	LPS-activated Scavenger Receptor SRECA1 can Induce entry of TLR4 into Lipid Microdomains, Mediate Signal Transduction and trigger cytokine release. <i>FASEB Journal</i> , 2015, 29, 888.25.	0.5	1

#	ARTICLE	IF	CITATIONS
91	Cell Fusion and Dendritic Cell-Based Vaccines. , 2011, , 315-350.		0